Nykode Therapeutics proposes chair of Zealand Pharma to lead own board

The board at Norwegian biotech firm Nykode Therapeutics, which is led by Danish CEO Michael Engsig, has proposed that the current Chairman at Zealand Pharma Martin Nicklasson also chairs the board at Nykode.

Martin Nicklasson, chair of Zealand Pharma, has been proposed as chair of Nykode Therapeutics | Photo: Zealand Pharma / PR

by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Published: 17.12.21 at 09:37

When Norwegian biotech firm Nykode Therapeutics meets for its general assembly on Dec. 22, a new face will join as chairman of the board of directors.

The company, which was named Vaccibody until recently, announces the board's decision to propose Martin Nicklasson as the new chair, replacing Anders Tuv, who has left the role but has remained as an ordinary member of the board.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

Ambu board had started headhunting process long before firing of CEO

With Chairman of Ambu Jørgen Jensen at the helm, the company's board decided to lay off chief executive Juan Jose Gonzalez on Thursday | Foto: Ida Munch/ERH

Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.

Nine new drugs recommended for approval by CHMP at May meeting

Foto: Peter Dejong/AP/Ritzau Scanpix

During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.

Britt Meelby Jensen wants to rebuild trust in Ambu

Britt Meelby Jensen, new CEO of Ambu | Foto: Novo Holdings / PR

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

Today, Juan Jose Gonzalez steps down from his role as chief executing of Ambu | Foto: Ambu/PR

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Top news from MedWatch this week

Miss anything?

Further reading

Related articles